FDA approves Novo Nordisk's Wegovy HD for chronic weight management in adults with obesity

The US FDA has approved Wegovy HD (semaglutide) injection 7.2 mg, a higher-dose formulation of Novo Nordisk's GLP-1 receptor agonist for chronic weight management in adults with obesity. The [approval](https://www.prnewswire.com/news-releases/fda-approves-novo-nordisks-new-wegovy-hd-injection-delivering-the-highest-weight-loss-to-date-for-a-wegovy-injection-adding-to-its-already-expansive-clinical-profile-302718982.html), announced on March 19, 2026, makes Wegovy HD the highest-dose injectable semaglutide formulation available for weight loss. The decision further extends the Wegovy label, which now spans multiple formulations — including an oral tablet approved in December 2025 — and carries indications not held by any other GLP-1 medication marketed for weight management, including cardiovascular risk reduction in adults with established heart disease and obesity or overweight. Wegovy HD is indicated for use alongside a reduced-calorie diet and increased physical activity in adults with obesity (BMI ≥30 kg/m²) who have tolerated the 2.4 mg dose for at least four weeks and for whom additional weight reduction is clinically indicated. The approval does not extend to patients with diabetes, reflecting the trial population studied. The 7.2 mg dose is administered once weekly by subcutaneous injection, following the same dosing schedule as the existing 2.4 mg formulation. Novo Nordisk said Wegovy HD will be available in April through pharmacies and other channels across the US. The approval was based on results from the [STEP UP trial](https://www.thelancet.com/journals/landia/article/PIIS2213-8587(25)00001-2/fulltext), a Phase IIIb, 72-week, randomized, double-blinded, placebo-controlled and active-controlled study that enrolled 1,407 adults with BMI ≥30 kg/m² without diabetes. Participants were randomized 5:1:1 to receive once-weekly semaglutide 7.2 mg, semaglutide 2.4 mg, or placebo, all as adjuncts to lifestyle intervention. At 72 weeks, the 7.2 mg dose produced mean body weight reductions of 20.7% under the efficacy estimand (assuming all patients remained on treatment) and 18.8% under the treatment regimen estimand (regardless of adherence), compared with 17.5% and 15.5% for the 2.4 mg dose and 2.4% and 3.9% for placebo, respectively. Approximately 31% of participants receiving the 7.2 mg dose achieved weight loss of 25% or greater, compared with 15.3% in the 2.4 mg group and 0% with placebo. The most common adverse reactions included nausea, vomiting, constipation, abdominal pain, fatigue, and headache. A new safety signal emerged: dysesthesia and related altered skin sensations were reported in 22% of those receiving 7.2 mg, compared with 6% at 2.4 mg and 0.3% with placebo. The approval arrives at a time of intensifying competition in obesity pharmacotherapy. Eli Lilly's Zepbound (tirzepatide), a dual GLP-1/GIP receptor agonist approved in November 2023, has demonstrated weight loss of up to 22.5% at its highest dose. The incremental weight loss offered by Wegovy HD — roughly three percentage points above the 2.4 mg dose — narrows the gap between the two products, though cross-trial comparisons carry inherent limitations. Meanwhile, several next-generation molecules are advancing through late-stage development, including Eli Lilly's retatrutide (a triple GLP-1/GIP/glucagon agonist), orforglipron (an oral non-peptide GLP-1 agonist), and Novo Nordisk's own CagriSema and amycretin, which combine GLP-1 activity with amylin-based mechanisms. Whether Wegovy HD's dose escalation strategy can maintain Novo Nordisk's position as these agents approach regulatory decisions remains an open question. The dysesthesia signal at the 7.2 mg dose, which was not observed at comparable rates with the lower dose, will also require monitoring in broader clinical use. --- Spot something wrong? [Report an issue with this article](https://newsgen-prod.reframedata.com/feedback/wegovy-hd-approved-fda-approves-novo-nordisks-for)